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Abstract  
Background: Medication adherence is the process by which patients take their medication as 
prescribed and is an umbrella term that encompasses all aspects of medication use patterns. 
Ambiguous terminology has emerged to describe a deviation from prescribed regimen, forcing 
the European ABC Project to define three phases of medication use: “Initiation, 
Implementation, and Discontinuation”. However, different measures of medication 
adherence using medication records are currently available that do not always distinguish 
between these phases. The literature is lacking standardization and operationalization of the 
assessment methods. Objective: To propose a harmonization of standards as well as 
definitions of distinct measures and their operationalization to quantify adherence to 
medication from medication records. Methods: Group discussions and consensus process 
among all coauthors. The propositions were generated using the authors’ experiences and 
views in the field of adherence, informed by theory. Results: The concepts of adherence 
measures within the new taxonomy were harmonized, and the standards necessary for the 
operationalization of adherence measures from medication records are proposed. Besides 
percentages and time-to values, the addition of a dichotomous value for the reinitiation of 
treatment is proposed. Methodological issues are listed that should be disclosed in studies on 
adherence. Conclusions: The possible impact of the measures in adherence research is 
discussed. By doing this, the results of future adherence research should gain in accuracy. 
Finally, studies will become more transparent, enabling comparison between studies. 
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Introduction 
Medication records are increasingly collected 
worldwide and available from different 
sources such as prescribing, dispensing, or 
reimbursement databases. The ready 
availability of these records has stimulated 
widespread use of these data to study 
patterns of medication use and assess 
medication adherence in daily clinical 
practices. Medication records often contain 
several elements required to calculate the 
number of days’ supply, such as the date of 
prescribing or dispensing, the quantity 
dispensed, and the prescribed daily dosage 
(PDD). Differences in information that is 
available may exist between Europe and the 
United States. As an example, the 
instructions to patients (ie, the daily dosage 
information, such as, “Take 1 tablet 2 times 
daily”) are rarely contained in US prescription 
claims. Nevertheless, the US data set might  
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have the days’ supply included when the 
pharmacy staff has access to the dosing 
instructions and calculates the days’ supply 
with its subsequent entry into the computer 
processing system. Nevertheless, calculations 
with medication records represent a simple 
approach to determine how much of the 
prescribed medications are being taken (ie, 
adherence) and for how long (ie, 
persistence). These measures have intuitive 
appeal, and their value in clinical research has 
been shown.1,2 They are objective, 
noninvasive, and economical for use in large 
populations because they can be easily 
derived from data routinely collected for 
administrative or other purposes. The 
reported calculations of adherence from 
medication records are indubitably based on 
the above-mentioned elements, but 
specification of standards for these 
calculations is missing.3-5 In the absence of 
any gold standard, no less than 11 different 
methods for calculating adherence were 
identified by Hess et al,6 the most often used 
being the MPR (medication possession ratio) 
and the proportion of days covered (PDC).7 
When applying the 11 different calculation 
methods to the same set of pharmacy data, 
Hess et al6 obtained adherence rates ranging 
from 63.5% to 104.8%, demonstrating the 
dramatic influence of the methods on the 
computed adherence values. Wilke et al8 
identified 47 publications with pharmacy 
claims using 12 different calculation 
methods. When applied to a simulation with 
reimbursement data of 113 108 patients, the 
adherence ranged between 15.7% and 
97.0%. In fact, of the 47 publications, only 4 
named all the elements that were included in 
the calculations.8 Similarly, Caetano et al3 
identified 5 different methods for calculating 
persistence, which resulted in a wide range of 
values and interpretations when applied to a 
hypothetical patient. In some cases, 1 
isolated refill beyond the 360 days following 
treatment start was sufficient to qualify a 
patient as persistent.9 Authors publishing 
adherence rates mostly omit a description of 
the operationalization of the assessment 
methodology5 – that is, how the adherence 
measures were calculated. This lack of 
transparency regarding the 
operationalization of adherence measures 
complicates the comparison of adherence 
results across studies6,10,11 and the 
translation to real-world practice.9  
In parallel, and almost inevitably, a 
proliferation of terms emerged in the 
literature to describe medication use.12 They 
all describe a deviant behavior and are often 
used interchangeably but define different 
aspects such as seeking medical care, 
acquiring medication, or deviating from the 
prescribed therapeutic plan.12 As a 
consequence, a European consortium 
defined a new taxonomy for the umbrella 
term adherence to medications, which is “the 
process by which patients take their 
medications as prescribed”.12 It is divided 
into 3 quantifiable phases: initiation, 
implementation, and discontinuation. 
Persistence represents one aspect of 
adherence and encompasses the time over 
which a patient remains on treatment. In this 
context, standards and definitions are 
needed to calculate the adherence measures 
according to the recently proposed 
taxonomy.12 
 
Aims and Objective 
The aims were (a) to harmonize the concepts 
of adherence measures from medication 
records within the new taxonomy; (b) to 
propose the standards necessary for the 
operationalization of these adherence 
measures; (c) to refine adherence calculation 
with medication data; and (d) to list the 
methodological issues that should be 
disclosed. 
 
Methods 
Six researchers with considerable expertise in 
medication adherence from Switzerland and 
the Netherlands - 2 leading European 
countries in the integration of adherence 
measurements from medication records into 
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pharmacy systems - formed a panel in 
summer 2014. All members were researchers 
from academia and involved in governmental 
projects, and 2 members were doctoral 
candidates who worked on calculation 
methods. All are members of ESPACOMP 
(European Society for Patient Adherence, 
Compliance and Persistence); 2 are founding 
members, and 1 a former president. The 
leadership was taken by a member of the 
Special Interest Group on Adherence from 
the European Society of Clinical Pharmacy. 
Because the lack of standardization of 
adherence measures is a tenacious problem 
in adherence research, the panel decided to 
propose recommendations for future 
adherence research. A consensual nature of 
the process based on recent methodological 
articles12,13 and discussion among experts 
was selected to generate first results in 
November 2014. Final consensus on the last 
version was obtained in July 2015. The 
concepts describing medication use behavior 
were harmonized; standards were set for the 
elements related to the (re)fill of a 
prescription; and the measures were refined, 
together with their basic calculations capable 
of quantifying the 3 phases of adherence. 
 
Results 
Harmonization of Concepts and Proposed 
Measures Describing Adherence 
 
Because medical records contain variables 
that are mostly specific to their source – that 
is, quantity prescribed in prescription records 
versus quantity dispensed in dispensing 
records - some variable might be lacking for 
some calculation. The assumptions for 
adherence measurements with pharmacy 
dispensing records are listed in Box 1. 
 
Initiation of the treatment occurs when the 
patient takes the first dose12 and represents 
a dichotomous variable, based on first-fill 
data. With prescribing and dispensing 
records at disposal, sometimes, initiation is 
defined as the time from prescription until 
the first medication fill14 – that is, a time-to-
event variable. To reduce confusion, it should 
be named time-to-initiation. In any cases, the 
output is the number of primary nonadherers 
– that is, patients with a prescription that is 
not followed by a dispense. 
 
Implementation is achieved when the 
patient’s actual dosing is compared with the 
prescribed dosing regimen, from initiation 
until the last dose is taken.12 For this phase, 
several measures are proposed.  
 
Discontinuation and persistence are driven 
by the continuity of medication refilling. 
Discontinuation occurs when the next due 
dose is omitted and no more doses are taken 
thereafter. Discontinuation is, therefore, a 
dichotomous variable. Persistence describes 
the time from initiation until last dose12 – that 
is, the end of therapy. Persistence is, 
therefore, a time-to-event variable. The 
dimension of time is an integral part of both 
terms.4 Exceeding a maximal permissible 
length without supply (grace period) qualifies 
for discontinuation or nonpersistence. This 
maximal gap can range from zero to an 
infinite number of days. Between those 2 
extremes, almost every gap length from 7 to 
180 days has been proposed in the 
literature.15 Setting the cutoff is equivalent to 
defining the sensitivity of the measure 
because the smaller the allowable gap, the 
higher the number of patients classified as 
having discontinued or being 
nonpersistent.16 A 90-day allowable gap 
might be adequate to detect true 
nonpersistence because a study investigating 
the impact of several gap selections on 
persistence observed no major change with 
increasing gap days >90 days.17 Ultimately, 
however, the length of the permissible gap 
should depend on the medication(s)/ 
condition(s) being studied. 
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Box 1. Assumptions Underlying Adherence 
Measures With Pharmacy Medication Records. 
 
 Medication records are complete, comprehensive, 
and accurate 
 The first intake occurred on the day of the first fill 
 The medication is taken as indicated (eg, tablet 
ingested) 
 Lack of a refill equals a medication is not consumed 
after the oversupply is exhausted 
 Medications are not purchased or borrowed from 
another person or venue 
 No unknown treatment interruptions or dosing 
changes occurred during the observation period 
 
 
Because patients may restart treatment at 
any point in time, the quantification of 
reinitiation of treatment is proposed as the 
proportion of patients with a dispensing after 
the maximal predefined gap length. 
 
Definition of Standards 
 
The definitions of the elements with 
standards and calculations are summarized in 
Table 1. 
The observation period is defined as the 
length of time over which the adherence 
measures are assessed. The period should 
start at t1 at the first (re)fill date, with the 
assumption that the patient starts 
medication intake that very day. The period 
should end either at the last refill date tn or at 
an arbitrary date ta (eg, a medication review 
date; t1 + 360 days). The rationale for such 
variable end dates is that refills are time-
dependent events.  
 
The number of days’ supply is defined as the 
quantity dispensed divided by the PDD. The 
latter equals the amount of medication to be 
consumed per day and is calculated with the 
dosing instruction as Unit(s) per dose x 
Dose(s) per day. Changes in dosage regimen 
according to medical prescription should be 
accounted for and should be exhaustively 
described. If the data set does not contain the 
quantity dispensed as a variable, it should not 
be used. 
Table 1. Definitions of the Elements, With 
Standards and Calculation.a 
 
 
Element 
 
Definition 
Standards and 
calculation 
Start and end 
points of the 
observation 
period 
Period starts at t1 
and ends at tn or ta  
t1 = date of first 
(re)fill 
tn = date of last refillb 
ta = arbitrary dateb 
Observation 
period 
Number of days of 
the entire periodb 
tn - t1 or ta – t1 
Quantity 
dispensed 
Number of 
dispensed 
medication units 
(eg, tablets) 
[quant_disp]c 
Prescribed daily 
dosage (PDD) 
Amount of units to 
be consumed per 
day according to 
the dosing 
instructions 
PDD = Number of 
units per dose x 
Number of doses per 
day c 
Number of days’ 
supply (An) 
Number of days 
with medication 
available 
[quant_disp]/[PDD] 
Refill interval (Bn) Number of days 
between 2 
dispensations 
(Refill date tn) - (Refill 
date tn-1) 
Oversupply Number of days’ 
supply accumu-
lated from 
previous dispen-
sings (stockpile) 
If (An > Bn), then 
oversupply = (An - Bn) 
Gap Number of days 
without medica-
tion supply 
If (An < Bn), then gap 
= (Bn - An) 
Maximal gap 
length 
Number of days of 
the longest period 
of time without 
supply (after 
taking carryover of 
oversupply into 
consideration) 
 
a See Figure 1 for graphical representation. 
b a and n are integral numbers. 
c Can be an integral or a fractional number. 
 
 
With data sets that contain PDD as a variable, 
if the dosing instruction is missing, 
extrapolation from the following interval (for 
t1) or from the previous interval (for all other 
t) should be allowed. A data set should be 
excluded if dosing instruction is missing for 2 
intervals in a row or if the instruction changed 
over time and is unknown. With data sets 
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that typically do not contain dosage 
instructions as a variable, noticeable 
differences may result from assumptions 
made.18 Researchers should, thus, explicitly 
state what assumptions were made to 
estimate the numbers of days’ supply. 
 
Oversupply (or stockpiling) results from 
overlapping days’ supply of subsequent refill 
intervals and equals to accumulated 
medications. Oversupply should be allowed, 
with the rationale that patients get supply 
before they have exhausted their drug supply 
and in a flexible manner according to their 
daily activities and duties. It should be carried 
forward to the next interval (carryover) or at 
the end of a period with a gap, with the 
rationale that this pattern reflects real life - 
patients exhausting previous supply before 
starting the new one. Retroactive 
compensation - that is, the use of an 
oversupply to compensate a gap that 
occurred earlier in the dosing history - should 
be forbidden. Results of a study with 
hypothetical dispensing patterns suggest that 
accounting for oversupply in adherence 
measurement (time-forward approach) 
performs better than other methods.10 
Oversupply beyond the observation period 
should not be permitted – that is, extra doses 
beyond the end of the observation period 
should be excluded. Oversupply beyond the 
end date was shown to overestimate 
adherence measures6 by inflating the value of 
the quantity dispensed. 
 
A gap may exist between refills when prior 
supply is depleted before refill supply is 
available. It should be compensated to the 
extent possible by any existing oversupply 
from a prior interval. Hospitalization or 
residence in a long-term care facility may lead 
to apparent gaps in pharmacy refills and are 
often interpreted as discontinuation, mostly 
because they remain unrecognized. If known, 
the hospitalization period should be 
subtracted from the denominator, assuming, 
first, complete adherence to hospital drugs 
during hospital stay and, second, that 
patients do not obtain medications at 
discharge, and with the rationale that the 
amount of previous medication at the 
disposal of the patients after discharge is 
identical to that before hospitalization. A 
similar approach was used in a study 
developing an adherence index with inhaled 
corticosteroid.19 Unsurprisingly, adjusting for 
the time a patient was hospitalized by 
excluding the days of the hospitalization 
marginally influences the adherence rate – 
that is, the adherence value is approximately 
0.5% lower than without accounting for 
hospitalization days.7 If patients use their 
home medication in the hospital, no 
adaptation of the calculation is needed.  
 
Switching is defined as one product being 
initially filled, then a different product in the 
same therapeutic class being filled at a latter 
point within the observation period, and the 
initial product is no longer filled. Generic 
switching is defined as switching between 
products with identical ATC code on level 5 
(eg, C03EB01: Lasix 40 mg and Furosemide 
Actavis 40 mg). In this case, switch is 
considered as the possession of 2 products 
one after the other, and carryover is granted 
under the above-mentioned conditions. 
Therapeutic switching is defined as 2 
different medications – that is, different ATC 
code on level 5 (eg, A02BC01: Omeprazole 40 
mg and A02BC02: Pantoprazole 40 mg; 
switching within chemical group) or on level 
4 (eg, A02BC: proton pump inhibitor and 
A02BA: H2-antagonist; switching within 
pharmacological group). In this case, switch is 
considered as continuous use, and no overlap 
is granted – that is, a possible oversupply of 
one medication should be disregarded, with 
the rationale that a medical reason forced the 
physician to change medication (eg, lack of 
effectiveness, side effects, or intolerance). 
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Mandatory Information in Adherence Studies 
in Which Medication Records Are Used 
 
To facilitate formal comparison between 
adherence studies published in the literature, 
some information should be clearly disclosed 
(Box 2). The issues are related to the 
operationalization of the adherence 
measures, which could dramatically influence 
the above-mentioned results. 
 
Refinement of Calculation 
 
Implementation is best given by the 
cumulative proportion of time at which 
medications are available – that is, in the 
possession of the patient. For monotherapy, 
the basic algorithm of the MPR is proposed. It 
sums the number of days’ supply (see 
calculation below), divided by the number of 
days in the observation period, multiplied by 
100. Some researchers and guidelines include 
the days’ supply for the last prescription 
dispensed (up to the end of the observation 
period) in adherence and persistence 
calculations.20 However, oversupply beyond 
the observation should be excluded (see 
above), and the following calculation should 
be used: 
 
If end date is tn (last refill date), then the 
numerator is [(Sum of days’ supply) - (Days’ 
supply obtained at tn)]. 
 
If end date is ta (arbitrary date), then the 
numerator is [(Sum of days’ supply without 
the last dispensing) + (Days’ supply obtained 
at the last dispensing up to the end date of 
the period ta). 
 
The MPR ranges from 0% to 100%. 
 
For polypharmacy, the basic algorithm of 
DPPR (daily polypharmacy possession ratio) is 
proposed. It has been described elsewhere.13 
The DPPR does not result from an equation 
but from the application of a stepwise 
algorithm. In brief, the number of all  
Box 2. Issues to Clearly Disclose in Adherence 
Studies. 
 
1. How was the data sample derived? (reimbursement, 
dispensing, prescribing data) 
2. Was there a minimum number of fills and how was 
the minimum number of (re)fills defined? 
3. Were all or only newly treated patients assessed? 
What was the definition of a newly treated patient? 
4. Which adherence phase was assessed? (initiation, 
implementation, discontinuation) 
5. How long was the observation period and how was it 
defined? (first vs last refill dates or first vs arbitrary 
end date) 
6. How was the prescribed daily dose defined? 
(instructions for use, assumptions  derived from 
treatment guidelines) 
7. Was a single medication or polypharmacy analyzed? 
8. How were hospitalization periods taken into 
account? 
9. Which was the rationale for the use of threshold? 
(grace period, medication possession ratio) 
10. How were missing values handled? 
11. How were generic or therapeutic substitution 
handled? 
12. How was dose switching handled? 
 
 
medications available is determined for each 
day separately over the observation period. A 
score between 0 (no medication available) 
and 1 (all medications available) is set. To 
obtain the proportion of all medications 
available for daily use, one has to sum the 
scores, divide by the number of days in the 
observation period, and multiply by 100. The 
DPPR ranges from 0% to 100%.  
 
The basic algorithm for oversupply is 
(Number of days’ supply An) - (Days in the 
refill interval Bn) if An > Bn (Figure 1). The basic 
algorithm for gap is (Days in the refill interval 
Bn) - (Number of days’ supply An) if An < Bn 
(Figure 1). They are calculated 
simultaneously for each interval and summed 
up from one interval to the other. Because 
the use of an oversupply to compensate a gap 
that occurred earlier in the dosing history is 
forbidden (retroactive compensation), 
oversupply always has a value ≥0 (negative 
supply cannot exist).  
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Figure 1. Graphical representation of the elements defined in Table 1. The observation period runs 
from the start day (t1 at the first dispensing date) to the end day (tn at the last dispensing date, or ta at 
an arbitrary date); A is the number of days with medication available, and B is the number of days 
between 2 dispensings. Oversupply obtained from A1 is carried forward to the next possible interval 
(arrow) at the end of A3, which is likely to occur in the real world. Oversupply obtained from A4 is 
disregarded if tn is the end date and added at the end of A6 if ta is the end date. 
 
 
Implementation is also depicted by the days 
without sufficient medication supply (gaps). 
The basic algorithm for the time without 
supply sums the number of days without 
supply after each interval (after taking 
oversupply from previous intervals into 
consideration; see Figure 1) divided by the 
number of days of the observation period, 
multiplied by 100. Last supply dispensed at 
the end of the observation period should be 
excluded. The value ranges from 0% to 100%. 
Because this value does not capture the 
dynamics of the gaps, further measures are 
proposed. The maximum gap length is the 
number of days of the longest period of time 
without supply (after taking carryover of 
oversupply into consideration). The mean 
gap value ± standard deviation can be an 
indicator of dispersion. 
 
Discontinuation and Persistence  
 
The maximum period without supply (gap) 
should be clearly defined. The clinical 
relevance of stopping therapy should guide 
the maximal allowed gap. Thus, with drugs 
with short half-lives or when outcome is 
linked to short-term drug effects such as 
cardiovascular or antidiabetic drugs, a 
shorter gap length can be justified, where 
patients are considered nonpersistent on the 
first day on which they would have exhausted 
their drug supply.21 Similarly, shorter gaps 
might detect clinically meaningful (“true”) 
nonpersistence, for example, for HIV or 
anticoagulants. After setting the allowable 
gap length, persistence is best summarized 
using a Kaplan Meier curve or as a percentage 
of patients who have discontinued treatment 
during a defined time period.22 A cutoff at 3 
to 6 months could be set to quantify the 
percentage of early discontinuers. 
 
Reinitiation 
 
Interruption of treatment and its subsequent 
reintroduction have been investigated, 
predominantly in HIV patients, where 
discontinuation(s) of treatment was shown to 
induce viral resistance23,24 and, ultimately, 
morbidity and mortality.21 In these studies, 
interruption was mostly self-reported25 or 
was not defined.26 In larger studies analyzing 
cohorts from national register, the 
probability of restarting a therapy with statin 
was estimated from gaps of different length 
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– that is, after reinitiation of treatment.27,28 
The proportion of patients reinitiating 
therapy should be calculated by dividing the 
numbers of patients with a dispensing 
beyond the end of the allowable maximum 
gap by the number of patients defined as 
having discontinued therapy. 
 
Discussion 
Standards and their operationalization are 
proposed to quantify adherence to 
medication from medication records of 
various sources within the new taxonomy of 
the European ABC Group.12 By doing this, this 
study builds on previous consensus-based 
work and links conceptual definitions to 
operational definitions.  
 
Possession-related measures were selected 
(MPR for single medication and DPPR for 
multiple medication) to quantify the 
implementation phase of adherence because 
they are easy to calculate and interpret (the 
higher the value, the higher the medication 
possession). In addition, by integrating the 
last medication fill into the denominator, the 
MPR measures implementation over the time 
period that the patient was actually using the 
medication (from first fill to last fill). This 
deviates from the US standard for 
performance indicator-based reimburse-
ment, which uses the PDC.29 PDC uses a fixed 
denominator, often 365 days (based on a 
calendar year or a year’s follow-up). Even 
more confusing, some researchers used the 
last medication refill as their end date in PDC 
calculations, and some others used a fixed 
end date in their MPR calculations, leading to 
inconsistencies in the literature. Thus, it 
could be helpful to use the last fill date 
exclusively for MPR measures and fixed end 
date for PDC measures. By doing this, the 
MPR value would indicate the quality of 
implementation in a single measure, whereas 
the PDC would be an indicator of both the 
quality and the length of implementation 
during a medication dosing history. 
 
Some researchers have claimed that periods 
of under- or oversupply of medication may be 
obscured with possession rates.15 This might 
be true because the usual method of 
calculation used so far does not account for 
duplication (simultaneous use of multiple 
agents from the same therapeutic class) and 
overlapping - the 2 parameters most 
frequently responsible for the general 
overestimation of adherence.30 The proposed 
standards regulate duplication and 
overlapping and, thus, eliminate major 
elements that distort calculation results. A 
special emphasis was set to avoid 
mathematical equations that would depict 
impossible situations in the real world, such 
as including the supply left over beyond the 
end of the study period. On the other hand, 
medication oversupply through early refills 
(ie, stockpiling) is likely to occur in the real 
world and should be allowed. The most 
restrictive standard consists of forbidding the 
use of an oversupply to compensate a gap 
that occurred earlier in the dosing history 
(retroactive compensation). The proposed 
considerations reflect real-world situations 
because negative supply cannot exist. 
Patients either have supply (positive value) or 
they have not (zero value). Consequently, a 
stepwise algorithm along the intervals 
instead of an overall equation is needed. This 
algorithm is clearly more complicated, but it 
identifies more precisely periods of time 
where medication availability was unlikely.  
 
The terms discontinuation and 
nonpersistence are used alternately to 
indicate the end of therapy. Confusion might 
occur when using nonpersistence as a 
dichotomous value because persistence is a 
time-to-event value. Choosing the term 
discontinuation might raise less doubts. 
Because medication records do not disclose 
what happens after the last dispense (ie, 
treatment stop or treatment holiday), 
uncertainty forces decisions to be made. 
Defining a cutoff value for the number of days 
without supply (grace period) beyond which 
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treatment is discontinued – that is, end of 
therapy - determines nonpersistence. Part of 
the challenge is to set a limit that avoids 
misclassification of patients who restart 
treatment after a period of discontinuation 
and would otherwise be lost to calculation if 
the grace period is too small. As a 
consequence, the assessment of reinitiation 
is proposed as a further measure in 
adherence research. By doing this, the cutoff 
value for discontinuation can still be applied, 
and prolonged gaps between refills, which 
may not signify cessation of therapy, will still 
be detected. It is likely that repetitive stop-
and-go patterns have dramatic influence on 
therapy, and they have seldom been 
evaluated properly.31 With the setting of 
different cutoff values for discontinuation or 
nonpersistence, early discontinuers can be 
assessed, and new fields in adherence 
research are open for investigation. 
Generally, the allowable grace period is 
driven by the time between scheduled refills, 
and a pharmacologic rationale is lacking for 
the definition of the grace period or the 
threshold MPR. One study32 defined an 
allowable interruption gap of 42 days in 
accordance with a previous clinical trial that 
reported a potential loss of efficacy of the 
drug of interest after an interruption of 6 
weeks.33 In most cases, the time between 
scheduled refills is an order of magnitude 
longer than the drug’s therapeutic effect. 
Nevertheless, the grace period should 
depend on the drug forgiveness, which allows 
larger gaps between scheduled doses 
without noticeable loss of pharmacological 
effect. In any case, the search for a universal 
value set to separate adherence from 
nonadherence is doomed to failure and can 
only result in contradictory results.34  
 
To reduce confusion and inconsistency, 
several terms are excluded from the 
proposed concepts, such as the index date. 
Although this term has been often used in 
recent literature as the date of first claim,35 it 
also indicates the date of a drug-treated 
event in epidemiologic matched cohort 
studies. Furthermore, the simple measure of 
refill rates is excluded – that is, a measure 
based on the number of refills during a 
specified period of time (flexible or 
anniversary model) - because the length of 
time between refills is given no 
consideration. In addition, the refill rate is 
implicit in a gap-based measure. The number 
of refills may nevertheless be a valuable 
calculation for medications that may be used 
as needed without detriment to the clinical 
condition. It may further be appropriate for 
medications such as orally inhaled asthma 
drugs, where information on days’ supply 
may be imprecise. 
 
The way in which raw data are obtained (eg, 
by pillcount; prescribing; dispensing, or 
administrative data; electronic monitoring of 
single or multiple medication) determines 
the content of the database. However, 
mandatory information for calculations still 
includes drug name, drug dosage or dosing 
instructions, quantity of drug dispensed at 
each (re)fill, and date of each prescription 
(re)fill. In situations where the database 
contains the days’ supply (as entered by the 
pharmacist, for example), calculations can be 
performed when drug name and refill dates 
are also known. Provided the records are 
complete, the proposed measures can be 
calculated indiscriminately with prescribing 
and dispensing databases. In this regard, it is 
interesting to see that, increasingly, 
nationwide personal electronic medicine 
profiles are stored online for electronic 
prescribing and electronic monitoring of 
medicine.36 However, a recent evaluation of 
the Danish system showed that it was yet 
unable to accurately detect nonadherence,36 
predominantly because of incorrect 
prescription information and missing dosage 
information. Experiences from the United 
States after the introduction of the Medicare 
Improvements for Patients and Providers 
Act37 in 2008 showed at least an increased 
use of e-prescribing in response to the 
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incentive program.38 Today and worldwide, 
the most accurate database remains the 
Dutch pharmacy dispensing system. It is 
worth noting that since January 1, 2014, 
Dutch physicians are obliged to use e-
prescribing, and most of them send the 
prescription electronically to the pharmacy.  
 
In future, the measures chosen by a 
researcher should be determined by the 
overall goals of the study – that is, clinical 
efficacy trials (eg, MPR of the study drug), 
selection of ambulatory patients at risk in 
order to initiate an intervention such as 
specific counseling (eg, nonpersistence with 
HIV medication), or conditions for 
reimbursement (eg, noninitiation). Much 
more, the study population should determine 
the cutoff values. As an example, the length 
of the observation period may vary 
depending on whether the study population 
is restricted to new or chronic users of the 
medications. Finally, because adherence is a 
complex behavior with several aspects, it 
cannot be caught in one number. In any case, 
a careful description of the definitions and 
operationalization used is crucial if 
comparisons between studies are to be 
made. 
 
Strengths and Limitations  
This study has several strengths. First, the 
proposed standards are close to a real-word 
setting and eliminate overestimation of 
adherence values. Second, the proposed 
measures build on the taxonomy established 
by the European ABC Project and pursue the 
work of promoting consistency for different 
experimental investigations. Third, the 
proposed measures take full advantage of the 
information available in many databases, 
which is not the case for most of the current 
measures of adherence or persistence. 
 
This study has some limitations. First, as is 
true of any indirect method of adherence 
assessment, the proposed measures are 
unable to confirm ingestion of the dispensed 
medication. As a consequence, they function 
as surrogate measures of medication 
adherence. However, they provide an 
estimate of the highest possible level of 
medication possession and, thus, can identify 
those patients not able to consume the 
medication in sufficient quantity. In that 
sense, the measures can be considered to 
have a high sensitivity. Second, different 
assumptions must be made, the main one 
being that all medication will be taken at the 
days’ supply indicated. However, a 
standardization of the assumptions will lead 
to comparable estimates of adherence across 
different studies. 
 
Conclusion 
By following the displayed propositions, 
results of future adherence research should 
gain in accuracy and in confidence, and 
results between studies should be 
comparable. Because the ultimate goal of 
adherence measurement is to improve 
patient care, the proposed measures could 
be used to set flags in electronic databases, 
based on which health professionals could 
select appropriate and effective 
interventions to move into practice. 
Researchers are invited to discuss this 
proposition of standards and to 
communicate their observations. Ultimately, 
generally approved standards are soon 
needed along with their operationalization, 
which could be endorsed by an umbrella 
society, so that health professionals, 
researchers, health authorities, and policy 
makers can make informed choices for the 
benefit of patients and society. 
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